The WACC of Biofrontera AG (B8F.DE) is 6.8%.
| Range | Selected | |
| Cost of equity | 8.00% - 13.70% | 10.85% |
| Tax rate | 4.50% - 20.60% | 12.55% |
| Cost of debt | 4.00% - 4.50% | 4.25% |
| WACC | 5.6% - 8.0% | 6.8% |
| Category | Low | High |
| Long-term bond rate | 2.6% | 3.1% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 1.05 | 1.65 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.00% | 13.70% |
| Tax rate | 4.50% | 20.60% |
| Debt/Equity ratio | 1.3 | 1.3 |
| Cost of debt | 4.00% | 4.50% |
| After-tax WACC | 5.6% | 8.0% |
| Selected WACC | 6.8% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for B8F.DE:
cost_of_equity (10.85%) = risk_free_rate (2.85%) + equity_risk_premium (5.60%) * adjusted_beta (1.05) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.